The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Factors to consider when choosing treatment for relapsed multiple myeloma patients
Where are we with precision medicine for CLL?
Smouldering myeloma: detection, risk stratification and defining a new standard of care
The potential of palbociclib for the treatment of FLT3-ITD+ AML